Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00096928 |
This is a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who are candidates for treatment with Raptiva.
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
managed care organizations, community or physician practices, and academic centers in the United States
Inclusion Criteria:
Exclusion Criterion:
Notes:
If you are a doctor who is interested in participating as a study site, contact the RESPONSE Registry hotline for more information.
If you are an interested patient, contact your dermatologist (or the doctor treating your psoriasis) regarding this study. A list of participating doctors is below. If your doctor is not listed, then he/she can call the RESPONSE Registry Hotline at 1-800-516-1505 for more information.
Study Director: | Ivor Caro, M.D. | Genentech |
Responsible Party: | Genentech, Inc. ( Clinical Trials Posting Group ) |
Study ID Numbers: | ACD3101g |
Study First Received: | November 17, 2004 |
Last Updated: | April 10, 2009 |
ClinicalTrials.gov Identifier: | NCT00096928 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Plaque Psoriasis RESPONSE Raptiva efalizumab |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |